Acumen Pharmaceuticals announced positive topline results from its Phase 1 study of a subcutaneous formulation of sabirnetug in healthy volunteers. The study found that weekly subcutaneous administration of sabirnetug was well-tolerated.
The systemic exposure achieved following subcutaneous administration supports further clinical development of this dosing option. Developing a subcutaneous formulation has the potential to decrease treatment burden and increase patient convenience.
This advancement is a strategic step towards offering more flexible administration options for sabirnetug, which could broaden its appeal and accessibility for patients with early Alzheimer's disease. The company will continue to assess the most efficient pathway forward for this formulation.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.